Nunaps

About Nunaps

Nunaps is a pioneering digital therapeutics company focused on developing innovative treatments for neurological disorders using advanced technology. The company operates in the healthcare sector, specifically targeting patients with brain damage-induced visual field defects. Nunaps' flagship product, Nunap Vision, is a Software as a Medical Device (SaMD) that employs Virtual Reality (VR) to provide visual perceptual training. This product is currently undergoing a pivotal clinical trial, which is the first of its kind approved by the Ministry of Food and Drug Safety (MFDS) in South Korea.

Nunaps serves a diverse clientele, including hospitals, rehabilitation centers, and individual patients who suffer from neurological conditions. The company leverages a multidisciplinary team of neurologists, software and game VR developers, engineers, AI scientists, perceptual psychologists, and mathematicians to bring together neuroscience, medicine, and IT. This convergence enables Nunaps to create cutting-edge medical solutions that are both effective and user-friendly.

The business model of Nunaps revolves around the development and commercialization of digital therapeutics. Revenue is generated through the sale of their SaMD products, licensing agreements, and potential partnerships with healthcare institutions and research organizations. By focusing on the identification of target biomarkers and the development of new digital therapeutics, Nunaps aims to expand its pipeline to address various brain disorders, positioning itself as a leading platform in the digital therapeutics market.